<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09214</article-id><article-id pub-id-type="doi">10.7554/eLife.09214</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-35688"><name><surname>Grosso</surname><given-names>Ana R</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35689"><name><surname>Leite</surname><given-names>Ana P</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5773-3211</contrib-id><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-11251"><name><surname>Carvalho</surname><given-names>Sílvia</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35690"><name><surname>Matos</surname><given-names>Mafalda R</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-11254"><name><surname>Martins</surname><given-names>Filipa B</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45735"><name><surname>Vítor</surname><given-names>Alexandra C</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-11256"><name><surname>Desterro</surname><given-names>Joana MP</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35691"><name><surname>Carmo-Fonseca</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-11171"><name><surname>de Almeida</surname><given-names>Sérgio F</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7774-1355</contrib-id><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Instituto de Medicina Molecular</institution>, <institution>Faculdade de Medicina da Universidade de Lisboa</institution>, <addr-line><named-content content-type="city">Lisboa</named-content></addr-line>, <country>Portugal</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dang</surname><given-names>Chi Van</given-names></name><role>Reviewing editor</role><aff id="aff2"><institution>University of Pennsylvania</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>agrosso@medicina.ulisboa.pt</email> (ARG);</corresp><corresp id="cor2"><email>sergioalmeida@fm.ul.pt</email> (SFdA)</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>17</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>4</volume><elocation-id>e09214</elocation-id><history><date date-type="received"><day>03</day><month>06</month><year>2015</year></date><date date-type="accepted"><day>16</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>© 2015, Grosso et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Grosso et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-09214-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.09214.001</object-id><p>Aberrant expression of cancer genes and non-canonical RNA species is a hallmark of cancer. However, the mechanisms driving such atypical gene expression programs are incompletely understood. Here, our transcriptional profiling of a cohort of 50 primary clear cell renal cell carcinoma (ccRCC) samples from The Cancer Genome Atlas (TCGA) reveals that transcription read-through beyond the termination site is a source of transcriptome diversity in cancer cells. Amongst the genes most frequently mutated in ccRCC, we identified <italic>SETD2</italic> inactivation as a potent enhancer of transcription read-through. We further show that invasion of neighbouring genes and generation of RNA chimeras are functional outcomes of transcription read-through. We identified the <italic>BCL2</italic> oncogene as one of such invaded genes and detected a novel chimera, the <italic>CTSC-RAB38,</italic> in 20% of ccRCC samples. Collectively, our data highlight a novel link between transcription read-through and aberrant expression of oncogenes and chimeric transcripts that is prevalent in cancer.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09214.001">http://dx.doi.org/10.7554/eLife.09214.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.09214.002</object-id><title>eLife digest</title><p>Mutations in genes play important roles in many types of cancer. However, mutations alone cannot explain all the biological changes that occur to cancer cells. For example, very few mutations have been linked with a type of kidney cancer called clear cell renal cell carcinoma (or ccRCC for short). Instead, scientists suspect that this cancer is largely caused by changes in the expression of particular genes so that certain cancer-promoting genes are more highly expressed, while other genes that would prevent tumor growth become less active.</p><p>One of the few genes that is often mutated in ccRCC is called <italic>SETD2</italic>. This gene is involved in processes that alter the structure of DNA, but do not alter the genes themselves. These “epigenetic” changes can alter how the instructions in genes are used to make proteins. The first step in making proteins is to use a section of DNA as a template to make molecules of messenger ribonucleic acid (mRNA) in a process called transcription. There are markers within a gene that show where transcription should start and stop to produce the mRNA required to make a particular protein. Epigenetic changes can mask these markers so that the cell produces longer mRNAs that incorporate instructions from neighboring genes.</p><p>It was not known how often these stop signs are ignored in ccRCC cells. Here, Grosso et al. compared transcription in normal cells and in ccRCC tumor cells from 50 different patients. The experiments show that more stop signs were ignored in many of the cancer cells, especially in cells with mutations in <italic>SETD2</italic>. This caused all or parts of neighboring genes to be transcribed along with the target gene and led to changes in the expression levels of these genes. For example, a cancer-promoting gene called <italic>BCL2</italic> was more highly expressed in these cells.</p><p>Furthermore, some of the mRNA molecules produced in these cancer cells may make “fusion” proteins that combine elements from several proteins. These fusion proteins may work differently to normal cell proteins and therefore might also promote the development of tumors. Grosso et al.’s findings reveal a new link between epigenetic changes and cancer.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09214.002">http://dx.doi.org/10.7554/eLife.09214.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>clear cell renal cell carcinoma</kwd><kwd>transcription read-through</kwd><kwd>cancer genes</kwd><kwd>BCL2 oncogene</kwd><kwd>RNA chimeras</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001871</institution-id><institution>Fundação para a Ciência e a Tecnologia</institution></institution-wrap></funding-source><award-id>PTDC/BIM-ONC/0384-2012</award-id><principal-award-recipient><name><surname>de Almeida</surname><given-names>Sérgio F</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001871</institution-id><institution>Fundação para a Ciência e a Tecnologia</institution></institution-wrap></funding-source><award-id>SFRH/BD/92208/2013</award-id><principal-award-recipient><name><surname>Matos</surname><given-names>Mafalda R</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001871</institution-id><institution>Fundação para a Ciência e a Tecnologia</institution></institution-wrap></funding-source><award-id>SFRH/BD/52232/2013</award-id><principal-award-recipient><name><surname>Vítor</surname><given-names>Alexandra C</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001871</institution-id><institution>Fundação para a Ciência e a Tecnologia</institution></institution-wrap></funding-source><award-id>IF/00510/2014</award-id><principal-award-recipient><name><surname>Grosso</surname><given-names>Ana R</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Transcription beyond annotated gene boundaries expands the diversity of the cancer transcriptome with overexpressed oncogenes and RNA chimeras.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal carcinoma. The genetics of ccRCC is dominated by either somatic or germline inactivating mutations in the <italic>VHL</italic> gene. Regarding the full spectrum of genomic alterations, ccRCC ranks amongst solid tumors with the lowest average number of point mutations, small indels (<xref ref-type="bibr" rid="bib11">Kandoth et al., 2013</xref>) and somatic copy number alterations (<xref ref-type="bibr" rid="bib25">Zack et al., 2013</xref>). These findings suggest that epigenetic events make a significant contribution for the deregulation of the oncogenic and tumor suppressor gene expression programs that drive ccRCC development and progression. In fact, mutations in ccRCC are frequently observed in epigenetic factors such as the chromatin-remodeler <italic>PBRM1</italic> and the histone modifying enzymes <italic>BAP1</italic> and <italic>SETD2</italic>, highlighting the central role of epigenetic regulation in this particular cancer (<xref ref-type="bibr" rid="bib6">Duns et al., 2010</xref>; <xref ref-type="bibr" rid="bib24">Varela et al., 2011</xref>; <xref ref-type="bibr" rid="bib4">Dalgliesh et al., 2010</xref>; <xref ref-type="bibr" rid="bib3">Creighton et al., 2013</xref>). Such mutations in genes that control the epigenome can strongly modulate the landscape of the tumor transcriptome via aberrant expression of global sets of genes. For instance, defects in transcription termination lead to read-through beyond the annotated 3’ gene boundary and have the potential to severely modify the transcriptome and to risk the integrity of vital gene expression programs (<xref ref-type="bibr" rid="bib16">Kuehner et al., 2011</xref>). Paradoxically, the prevalence and functional outcome of transcription read-through has not been thoroughly scrutinized in any cancer before. Here, we report an unprecedented transcriptional profiling of a cohort of 50 pairs of ccRCC tumor and normal matched samples from The Cancer Genome Atlas (TCGA). We show that transcription read-through is prevalent in ccRCC and found that high levels of transcription read-through correlate with poor survival rates. Amongst the most frequently mutated genes in ccRCC, we identify <italic>SETD2</italic> inactivation as a major driving force of impaired transcription termination and high levels of read-through. Moreover, we show that transcription read-through overruns and interferes with the expression of downstream genes. We identify the anti-apoptotic oncogene <italic>BCL2</italic> as one of such interfered genes, thereby illustrating a new mechanistic basis for the transcriptional deregulation of oncogenes. In addition, our transcriptome analyses revealed recurrent RNA chimeras generated from read-through episodes in ccRCC. RNA chimeras are common features of cancer cells formerly thought to be produced solely by chromosomal translocations. We now know that many chimeric transcripts can originate from DNA-independent events such as <italic>trans</italic>-splicing, RNA recombination or transcription read-through (<xref ref-type="bibr" rid="bib8">Gingeras, 2009</xref>). Our analyses revealed that read-through is a major source of RNA chimeras in ccRCC and identified a novel chimera, the <italic>CTSC-RAB38</italic>, in 20% of ccRCC tumors, but not in any normal matched sample. Altogether, our data disclose the prognostic power of transcription read-through and emphasizes its role as a major source of transcriptome diversity in ccRCC, namely via aberrant expression of cancer genes and RNA chimeras.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Transcription read-through is frequent in ccRCC</title><p>To investigate the prevalence of transcription read-through in ccRCC, we analysed RNA-seq data from 50 pairs of tumor and normal matched samples from TCGA (<xref ref-type="bibr" rid="bib1">Cancer Genome Atlas Research N, 2013</xref>). Compared to normal tissue, all tumor samples exhibited several genes with transcription termination defects revealed by a high number of reads mapping downstream the transcription termination site (TTS) (<xref ref-type="fig" rid="fig1">Figure 1A,B</xref> and <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1A</xref>). Such accumulation of reads results from transcription read-through beyond the TTS, a surrogate for deficient transcription termination (<xref ref-type="bibr" rid="bib9">Higgs et al., 1983</xref>). In agreement with a defect in transcription termination, we did not detect differences in read counts on any region upstream the TTS, contrasting with the significant increase in the intergenic region immediately downstream this site (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).<fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.09214.003</object-id><label>Figure 1.</label><caption><title>Transcription read-through is prevalent in ccRCC.</title> <p>(<bold><bold>A</bold></bold>) Top graph depicts the number of genes with transcription read-through per ccRCC sample. The heatmap illustrates the genes with (blue) and without (grey) transcription read-through. The left graph indicates the percentage of samples on which read-through is observed for each individual gene. (<italic>n</italic> = 50 tumor/matched normal ccRCC TCGA samples). (<bold><bold>B</bold></bold>) Heatmap representation of the RNA-seq profile distribution and fold change after the TTS region of genes with transcription read-through in one representative TCGA ccRCC sample (patient barcode TCGA-CZ-5465) of a total of 50 tumor and matched pairs analysed. The gene body region was scaled to 60 equally sized bins and ± 4 Kb gene-flanking regions were averaged in 100-bp windows. The left panel shows the read counts (log2 RPKMs) of the matched normal tissue in all genes with read-through and the right panel shows the fold-change (log2) of read counts between the tumor and the matched normal tissue. Genes are ordered according to the read-through length. Scales and colour keys for each panel are depicted in the bottom. (<bold><bold>C</bold></bold>) Metagene analysis of RNA-seq profiles for tumor and matched normal tissue from one ccRCC patient. *p&lt;0.05 by Student’s T-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09214.003">http://dx.doi.org/10.7554/eLife.09214.003</ext-link></p></caption><graphic xlink:href="elife-09214-fig1-v2.tif"/></fig></p><p>We then examined whether global deregulation of gene expression at the level of transcription termination affects overall survival rates of ccRCC patients. For that we segregated the TCGA samples into two categories: ‘high read-through’ samples (those with more than 200 genes with read-through) and ‘low read-through’ samples (less than 200 genes with read-through) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). We found that patients with a ‘high read-through’ phenotype died significantly earlier than patients with a ‘low read-through’ phenotype (p = 0.008, log-rank test; <xref ref-type="fig" rid="fig2">Figure 2B</xref>).<fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.09214.004</object-id><label>Figure 2.</label><caption><title>Transcription read-through correlates with ccRCC survival rates.</title><p>(<bold><bold>A</bold></bold>) The top graph indicates the number of genes with transcription read-through on each ccRCC patient sample. Samples were split in two groups according to the number of genes with transcription read-through (low or high), using 200 genes as a cut-off. The heatmap represents the RNA-seq tumor/matched normal fold change 4 Kb after the TTS region of genes with transcription read-through. (<bold><bold>B</bold></bold>) Kaplan-Meier plot comparing the survival of patients separated into ‘high read-through’ and ‘low read-through’ subsets as defined in <bold>A</bold>. (<bold><bold>C</bold></bold>) Proportion of ccRCC patient samples with low and high transcription read-through. Results are shown for samples containing any of the most recurrently mutated genes in ccRCC: <italic>SETD2, VHL, PBRM1, BAP1</italic> and <italic>MTOR</italic>. Proportions of high and low read-through were significantly different between samples carrying mutation in <italic>SETD2</italic> and in any of the remaining genes (Fisher’s Exact Test p&lt;0.05).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09214.004">http://dx.doi.org/10.7554/eLife.09214.004</ext-link></p></caption><graphic xlink:href="elife-09214-fig2-v2.tif"/></fig></p><p>To estimate the contribution of the five most frequently mutated genes in ccRCC (<xref ref-type="bibr" rid="bib1">Cancer Genome Atlas Research N, 2013</xref>) to the observed transcription termination defects, we calculated the percentage of samples carrying any of these mutations that fall within each of the two subsets defined above. Samples with mutations in the histone methyltransferase <italic>SETD2</italic> scored preferentially in the ‘high read-through’ category (58%) (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). In contrast, samples carrying any of the four other frequently mutated genes in ccRCC segregated equally between both groups (<italic>BAP1</italic>) or mainly in the ‘low read-through’ category (<italic>VHL, PBRM1, MTOR</italic>. <xref ref-type="fig" rid="fig2">Figure 2C</xref>). Mutations on other genes known to be required for transcription termination or pre-mRNA processing were rare and did not segregate specifically in any category (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1B</xref>). These data suggest that widespread transcription read-through is a distinctive hallmark of ccRCC and identify <italic>SETD2</italic> mutations as a putative contributing factor for this phenotype.</p><p>To further investigate the correlation between <italic>SETD2</italic> mutations and transcription read-through in ccRCC, we performed RNA sequencing of 2 <italic>SETD2</italic> wild type (wt) and 4 <italic>SETD2</italic> mutant ccRCC cell lines previously reported to have a marked reduction of H3K36me3 levels (<xref ref-type="bibr" rid="bib6">Duns et al., 2010</xref>; <xref ref-type="bibr" rid="bib2">Carvalho et al., 2014</xref>). The wt ccRCC cell line Caki2 showed the highest <italic>SETD2</italic> expression levels, comparable with those of a non-cancer kidney epithelial cell line (HEK293) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). For this reason, we chose Caki2 as the reference dataset for the pairwise analyses of the remaining wt (Caki1) and mutant (MF, AB, ER, FG2) samples. These analyses revealed transcription read-through in hundreds of genes on all ccRCC cell lines, with a significantly higher incidence in all <italic>SETD2</italic> mutant cells (<xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1C</xref>). A metagene analysis of genes with transcription termination defects in <italic>SETD2</italic> mutant cells revealed that expression levels vary significantly downstream the TTS, but not within the gene body or at the promoter region (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Moreover, heatmaps of the fold change of read counts between different cell lines depict a strong increase in the number of read-through reads in <italic>SETD2</italic> mutant cells (<xref ref-type="fig" rid="fig3">Figure 3D</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). To rule out the contribution of different genetic backgrounds in these cell lines, we interrogated RNA-seq data from: <italic>SETD2</italic> knockout (KO) ccRCC cells (<xref ref-type="bibr" rid="bib10">Ho et al., 2015</xref>); <italic>SETD2</italic>-depleted human mesenchymal stem (MS) cells (<xref ref-type="bibr" rid="bib17">Luco et al., 2010</xref>); and embryonic stem (ES) cells from <italic>Setd2</italic> KO mice (<xref ref-type="bibr" rid="bib26">Zhang et al., 2014</xref>). Again, when compared to wt cells, <italic>SETD2</italic>-deficient cells displayed increased read counts specifically in the region immediately downstream the TTS consistent with transcription read-through events (<xref ref-type="fig" rid="fig3">Figure 3E,F</xref>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref> and <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1D,E,F</xref>). Similar results were obtained upon RT-qPCR measurements of transcription read-through in three distinct genes 48 hr after depletion of <italic>SETD2</italic> from wt ccRCC cells by RNA interference (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>)<fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.09214.005</object-id><label>Figure 3.</label><caption><title>SETD2 mutations promote transcription read-through in ccRCC.</title><p>(<bold><bold>A</bold></bold>) <italic>SETD2</italic> expression levels (FPKMs) in HEK293 and ccRCC cell lines. (<bold><bold>B</bold></bold>) Number of genes with transcription read-through up to 4 Kb downstream the TTS. *p&lt;0.05 by Fisher’s Exact Test after comparing each <italic>SETD2</italic> mutant cell line with the <italic>SETD2</italic> wt cell line (Caki1); (<bold><bold>C</bold></bold>) Metagene analysis of genes showing transcription read-through in <italic>SETD2</italic> mutant and wt ccRCC cell lines. The gene body region was scaled to 60 equally sized bins and ± 4 Kb gene-flanking regions were averaged in 100-bp windows. *p&lt;0.05 by Student’s T-test; (<bold><bold>D</bold></bold>) Heatmap representation of RNA-seq profile distribution and fold change after the TTS region of genes showing transcription read-through. Genes were scaled and averaged as in <bold>C</bold>. The left panel shows the read counts (log2 RPKMs) of the <italic>SETD2</italic> wt cell line (Caki2) in all genes with read-through. The two right panels show the fold-change (log2) between each ccRCC cell line and the reference <italic>SETD2</italic> wt ccRCC cell line (Caki2). Genes are ordered according to the read-through length. Scales and colour keys for each panel are depicted at the bottom of the panel. (<bold><bold>E</bold></bold>) Metagene analysis (as detailed in <bold>C</bold>) of genes showing transcription read-through in <italic>SETD2</italic> KO and wt 786-O ccRCC cells. *p&lt;0.05 by Student’s T-test. (<bold><bold>F</bold></bold>) Analysis as described in <bold>D</bold> of RNA-seq data from <italic>SETD2</italic> KO and control 786-O ccRCC cell lines.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09214.005">http://dx.doi.org/10.7554/eLife.09214.005</ext-link></p></caption><graphic xlink:href="elife-09214-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.09214.006</object-id><label>Figure 3—figure supplement 1.</label><caption><title>SETD2 mutations in ccRCC cells promote transcription read-through.</title> <p>Heatmap and metagene of RNA-seq profiles for the following <italic>SETD2</italic> mutant ccRCC cell lines: MF (<bold><bold>A</bold></bold>), AB (<bold><bold>B</bold></bold>) and ER (<bold><bold>C</bold></bold>). Heatmap representation of RNA-seq profile distribution and fold change after the TTS of genes with transcription read-through. Gene body was scaled to 60 equally sized bins and ± 4 Kb gene flanking regions were averaged in 100-bp window. Genes are ordered according to the length of the read-through. Left panel shows read counts (log2 RPKMs) of the <italic>SETD2</italic> wt cell line (Caki2) in all genes with read-through. The right panel shows the fold-change (log2) for <italic>SETD2</italic> mutant vs <italic>SETD2</italic> wt (Caki2) ccRCC cell lines. Metagene of RNA-seq profiles for <italic>SETD2</italic> mutant and wt ccRCC cell line of genes showing transcription read-through. *p-value &lt;0.05 by Student’s T-test. Scales and color keys for each panel are depicted at the bottom of the panel.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09214.006">http://dx.doi.org/10.7554/eLife.09214.006</ext-link></p></caption><graphic xlink:href="elife-09214-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.09214.007</object-id><label>Figure 3—figure supplement 2.</label><caption><title>SETD2-depletion impairs transcription termination.</title><p>(<bold>A,B</bold>) Heatmap representation of RNA-seq profile distribution and fold change after the TTS region of genes showing transcription read-through. The left panel shows the read counts (log2 RPKMs) of all genes with read-through in control cells. The two right panels show the fold-change (log2) between <italic>SETD2</italic>-depleted and control human MS cells (<bold><bold>A</bold></bold>) and <italic>Setd2</italic> KO and wt mouse ES cells (<bold><bold>B</bold></bold>). Genes are ordered according to the read-through length. Scales and colour keys for each panel are depicted at the bottom of the panel. (<bold>C,D</bold>) Metagene analyses of RNA-seq profiles of control and <italic>SETD2</italic>-depleted human MS cells (<bold><bold>C</bold></bold>) and of <italic>Setd2</italic> KO and wt mouse ES cells (<bold><bold>D</bold></bold>). *p-value &lt;0.05 by Student’s T-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09214.007">http://dx.doi.org/10.7554/eLife.09214.007</ext-link></p></caption><graphic xlink:href="elife-09214-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.09214.008</object-id><label>Figure 3—figure supplement 3.</label><caption><title>SETD2-depletion impairs transcription termination in ccRCC cells.</title> <p>Caki2 cells were transfected with siRNA oligos against <italic>SETD2</italic> or the firefly luciferase (<italic>GL2</italic>) (control) 48 hr before RNA extraction. RT-qPCR was carried out with primers designed to detect transcription read-through in <italic>MRPL23, SEL1L3</italic> and <italic>FAM46A</italic>. The levels of <italic>SETD2</italic> mRNA expression are also shown. The amount of PCR product estimated by RT-qPCR was normalized to the levels of U6 snRNA.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09214.008">http://dx.doi.org/10.7554/eLife.09214.008</ext-link></p></caption><graphic xlink:href="elife-09214-fig3-figsupp3-v2.tif"/></fig></fig-group></p><p>We then investigated whether wt <italic>SETD2</italic> can rescue the transcription termination defects observed in <italic>SETD2</italic> mutant ccRCC cells. For that, we performed single-molecule RNA FISH after transient expression of GFP-tagged SETD2 in a <italic>SETD2</italic> mutant ccRCC cell line (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). RNAs produced upon transcription read-through of <italic>MRPL23</italic> and <italic>SEL1L3</italic> were visualized as foci obtained with RNA FISH probes targeting a region downstream the termination site. These foci were present in significantly higher number in GFP-negative cells than in wt SETD2-GFP expressing cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). This result reveals that expression of wt SETD2 is sufficient to revert the transcription termination defects observed in mutant cells. Altogether, these data support the view that SETD2 is necessary to guide correct transcription termination genome-wide and that mutations in this histone modifier gene cause aberrant transcription patterns in ccRCC.<fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.09214.009</object-id><label>Figure 4.</label><caption><title>SETD2 rescues the transcription termination defects of SETD2 mutant ccRCC cells.</title><p>(<bold><bold>A</bold></bold>) RNA FISH experiments on a <italic>SETD2</italic>-mutant ccRCC cell line (FG2) transiently expressing wt SETD2-GFP. Quasar570-labeled probes were designed against a region downstream the termination sites of <italic>MRPL23</italic> and <italic>SEL1L3</italic>. The arrows indicate single RNA transcripts generated by a transcription read-through event. (<bold><bold>B</bold></bold>) Quantification of the number of GFP-negative and GFP-positive cells containing more than 5 RNA FISH foci. Means and standard deviations from at least 50 cells from four individual experiments are shown. Scale bars: 10 μm. p&lt;0.01 by Student’s T-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09214.009">http://dx.doi.org/10.7554/eLife.09214.009</ext-link></p></caption><graphic xlink:href="elife-09214-fig4-v2.tif"/></fig></p></sec><sec id="s2-2"><title>Transcription read-through interferes with the expression of neighbouring genes</title><p>One possible functional consequence of aberrant transcription read-through is the invasion of adjacent downstream genes altering their expression levels. This <italic>trans</italic>-acting transcriptional interference mechanism may play important roles in cancer development and progression by deregulating the expression of relevant oncogenes and tumor suppressors (<xref ref-type="bibr" rid="bib20">Proudfoot, 1986</xref>). To test whether overrunning of neighbouring genes is a frequent outcome of transcription read-through in ccRCC, we analysed the expression levels of the entire intergenic region and of the gene located immediately downstream. In agreement with our prediction, there was a statistically significant increase in read counts along the intergenic region and within the body of the downstream gene of a tandem pair (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). This difference was still detected after the TTS of the downstream gene, but not within the upstream gene (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Overall, reading-through RNA polymerase II (RNAPII) molecules invaded an average of 20% of genes located downstream (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1A</xref>).<fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.09214.010</object-id><label>Figure 5.</label><caption><title>Transcription read-through overruns and interferes with the expression of neighbouring genes.</title><p>Heatmap (<bold><bold>A</bold></bold>) and metagene (<bold><bold>B</bold></bold>) profiles of the intergenic region and of the gene located downstream of a read-through event in one representative ccRCC TCGA sample (patient barcode TCGA-CZ-5465). Genes were scaled and averaged as in <xref ref-type="fig" rid="fig1">Figure 1</xref>. *p&lt;0.05 by Student’s T-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09214.010">http://dx.doi.org/10.7554/eLife.09214.010</ext-link></p></caption><graphic xlink:href="elife-09214-fig5-v2.tif"/></fig></p><p>We then asked if read-through levels correlate with the expression levels of the downstream gene across the TCGA dataset. Notably, expression of 52 out of 903 genes (6%) exhibited a statistically significant correlation with read-through levels of the upstream gene (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1G</xref>). From these, 51 genes were positively correlated and only one gene showed a negative correlation. Amongst positively correlated genes we found the anti-apoptotic oncogene <italic>BCL2</italic>. In support of its oncogenic role in kidney cancer, depletion of <italic>BCL2</italic> with antisense oligonucleotides inhibits ccRCC tumor growth in vitro and in vivo (<xref ref-type="bibr" rid="bib23">Uchida et al., 2001</xref>). We further observed that expression of <italic>BCL2</italic> is frequently increased in the tumor samples of the TCGA dataset when compared to the matched samples (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Importantly, augmented levels of <italic>BCL2</italic> mRNA and protein correlated positively with the levels of transcription read-through of the <italic>KDSR</italic> gene located immediately upstream (<xref ref-type="fig" rid="fig6">Figure 6B,C</xref>). Altogether, these data suggest that transcription termination defects interfere with the expression of neighbouring genes and illustrate a new paradigm for the aberrant expression of cancer-related genes, which may explain the upregulation of the <italic>BCL2</italic> oncogene in ccRCC.<fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.09214.011</object-id><label>Figure 6.</label><caption><title>Transcription read-through of the KDSR gene correlates with the expression of the BCL2 oncogene.</title><p>(<bold><bold>A</bold></bold>) Distribution of the correlation between the read-through and the expression levels of the downstream tandem genes. Significant correlation values (Benjamini-Hochberg adjusted p&lt;0.05) are represented in blue. (<bold><bold>B</bold></bold>) Correlation between the expression levels of <italic>BCL2</italic> and the read-through of the upstream <italic>KDSR</italic> gene. The graph depicts the fold-change of read counts for each tumor and matched normal pair. (<bold><bold>C</bold></bold>) Correlation between BCL2 protein levels and the <italic>KDSR</italic> read-through.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09214.011">http://dx.doi.org/10.7554/eLife.09214.011</ext-link></p></caption><graphic xlink:href="elife-09214-fig6-v2.tif"/></fig></p></sec><sec id="s2-3"><title>Transcription read-through is a source of RNA chimeras in ccRCC</title><p>RNAPII elongation beyond the annotated gene boundaries and invasion of an adjacent gene as a result of impaired transcription termination may result in the formation of hybrid transcripts collectively called RNA chimeras (<xref ref-type="bibr" rid="bib8">Gingeras, 2009</xref>). In addition to gene fusions (formed upon chromosomal translocations) RNA chimeras can originate from DNA-independent events such as <italic>trans</italic>-splicing, RNA recombination or transcriptional read-through (<xref ref-type="bibr" rid="bib8">Gingeras, 2009</xref>). Our analysis of ccRCC RNA-seq data revealed a high number of reads mapping at two distinct tandem genes, which are indicative of RNA chimeras generated by intergenic splicing following a read-through event (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1H</xref>). Analysis of the splicing pattern of these chimeras showed that most events join the second-last exon of the upstream gene with the second exon of the downstream gene (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). This pattern is compatible with the exon definition model according to which transcription termination is necessary for the selection of the terminal 3’ splice site (ss) (<xref ref-type="bibr" rid="bib19">Niwa et al., 1992</xref>; <xref ref-type="bibr" rid="bib7">Dye and Proudfoot, 1999</xref>). In the absence of transcription termination, the terminal 3’ss is evicted and the terminal 5’ss will splice together with the first 3’ss of the downstream gene, which emerges from the nascent transcript once RNAPII reaches the second exon (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Interestingly, the number of RNA chimeras detected correlated positively with the levels of transcription read-through (p = 0.003; R = 0.41) and was significantly higher in the sample group with a ‘high read-through’ phenotype defined above (<xref ref-type="fig" rid="fig7">Figure 7C</xref>).<fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.09214.012</object-id><label>Figure 7.</label><caption><title>Read-through RNA chimeras are prevalent in ccRCC.</title><p>(<bold><bold>A</bold></bold>) Circos plots showing the location of genes forming each RNA chimera detected on human ccRCC cell lines and TCGA samples. Chimeras are represented by curves inside the Circos. (<bold><bold>B</bold></bold>) Number of read-through RNA chimeras formed by intergenic splicing between the represented exons. (<bold><bold>C</bold></bold>) Number of read-through RNA chimeras in the low and high read-through sample subsets defined in <xref ref-type="fig" rid="fig2">Figure 2A</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09214.012">http://dx.doi.org/10.7554/eLife.09214.012</ext-link></p></caption><graphic xlink:href="elife-09214-fig7-v2.tif"/></fig></p><p>A remarkable feature of these RNA chimeras is that some were recurrently detected in different tumor samples. One particular chimera, encoded by two consecutive genes - <italic>CTSC</italic> and <italic>RAB38 -</italic> was detected in 20% of the TCGA samples (but not in any matched normal sample) and in four of the six ccRCC cell lines that we sequenced de novo (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1H</xref>). We validated this RNA chimera by RT-qPCR before and after transfection of the ccRCC cell lines with a small interfering RNA (siRNA) spanning the transcript break-point, which resulted in a robust depletion of <italic>CTSC-RAB38</italic> (<xref ref-type="fig" rid="fig8">Figure 8A,B</xref>). In contrast, siRNAs targeting either the last exon of <italic>CTSC</italic> or the first exon of <italic>RAB38</italic> (which are not included in the chimeric transcript) significantly decreased the levels of <italic>CTSC</italic> and <italic>RAB38</italic>, respectively, but not the levels of the <italic>CTSC-RAB38</italic> chimera (<xref ref-type="fig" rid="fig8">Figure 8B,C</xref>). Moreover, we measured the RNAPII occupancy throughout the intergenic region and within the body of the <italic>CTSC</italic> and <italic>RAB38</italic> genes by chromatin immunoprecipitation (ChIP). We detected a robust occupancy of RNAPII throughout the intergenic region (<xref ref-type="fig" rid="fig8">Figure 8D</xref>), which further suggests that the <italic>CTSC-RAB38</italic> chimera is generated following a read-through episode without any genomic deletion or translocation involved.<fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.09214.013</object-id><label>Figure 8.</label><caption><title>The CTSC-RAB38 chimera is recurrently detected in ccRCC.</title><p>(<bold><bold>A</bold></bold>) Schematic illustration of the <italic>CTSC-RAB38</italic> locus depicting the position of the primers used to measure the transcripts levels by RT-qPCR shown in (<bold><bold>B</bold></bold>) and (<bold><bold>C</bold></bold>) and the position of the siRNAs targeting each of the three transcripts (<italic>CTSC, RAB38</italic> and the <italic>CTSC-RAB38</italic> chimera). The dashed curve in the scheme illustrates the splicing pattern of the chimeric transcript. (<bold><bold>B</bold></bold>) Relative expression of the <italic>CTSC-RAB38</italic> chimeric transcript after depletion of the indicated transcripts by RNAi in three distinct ccRCC cell lines (FG2, MF, ER). (<bold><bold>C</bold></bold>) Relative expression of <italic>CTSC</italic> and <italic>RAB38</italic> upon depletion of the indicated transcripts by RNAi in FG2 cells. Similar results were obtained with the other ccRCC cell lines. *p&lt;0.05 by Student’s T-test compared to controls. (<bold><bold>D</bold></bold>) RNAPII ChIP along the <italic>CTSC-RAB38</italic> locus in FG2 cells. Means and standard deviations from five independent experiments are shown. *p&lt;0.05 by Student’s T-test compared to the gene desert.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09214.013">http://dx.doi.org/10.7554/eLife.09214.013</ext-link></p></caption><graphic xlink:href="elife-09214-fig8-v2.tif"/></fig></p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Our transcriptome analysis of a large dataset of tumor and normal matched samples revealed that transcription events extending beyond the annotated 3’ end of genes are frequent in ccRCC. Strikingly, our analysis further disclosed an unexpected prognostic power of transcription read-through in kidney cancer: higher number of genes with transcription read-through correlates significantly with poorer patient survival. Amongst the most frequently mutated genes in ccRCC, we identified <italic>SETD2</italic> inactivation as a contributing factor for increased transcription read-through. In fact, ectopic expression of <italic>SETD2</italic> was sufficient to rescue the transcription termination defects of <italic>SETD2</italic> mutant ccRCC cells. Moreover, we report that the effects of impaired transcription termination are not confined to the affected gene. Instead, it also contaminates the expression of neighboring genes that are overran by reading-through RNAPII complexes. Importantly, amongst the genes whose expression directly correlates with the volume of transcription read-through on the upstream gene, we detected the anti-apoptotic oncogene <italic>BCL2</italic>. This finding unveils a new source of aberrant expression of cancer-related genes and provides a plausible mechanistic basis for the upregulation of <italic>BCL2</italic> frequently observed in ccRCC.</p><p>Our present study further reveals recurrent RNA chimeras in ccRCC combining sequences from two tandem genes. Such chimeras are generated following extensions of RNAPII beyond the annotated gene boundaries and invasion of an adjacent gene as a result of impaired transcription termination. According to the exon definition model (<xref ref-type="bibr" rid="bib19">Niwa et al., 1992</xref>; <xref ref-type="bibr" rid="bib7">Dye and Proudfoot, 1999</xref>), deficient transcription termination is expected to impair the splicing of the last exon. In agreement, most chimeras skip the last exon of the upstream gene and the prevailing splicing pattern joins the second-last exon of the upstream gene with the second exon of the downstream gene. The finding that several of these RNA chimeras are recurrently detected in two or more tumor samples, suggests that they were selected during cancer development and supports the exciting possibility that they may play relevant functional roles.</p><p>Although our study primarily focused on the characterization of the transcription termination defects and their impact on the ccRCC transcriptome, our pioneer findings raise intriguing questions such as: which mechanism(s) drive such transcription defects?; how individual RNA chimeras are functionally involved in tumorigenesis?; do chimeric transcripts produce functional oncoproteins and/or can they directly affect the expression of other relevant cancer genes?; how can we intervene therapeutically to restore the canonical transcription pattern? The widespread incidence of aberrant termination in ccRCC cells suggests that it may play important roles in expanding the transcriptome diversity that drives cancer development and progression. The impact on <italic>BCL2</italic> expression illustrates a relevant functional outcome of transcription read-though. The generation of chimeric transcripts, namely those recurrently identified in several samples, such as <italic>CTSC-RAB38</italic>, further discloses the contribution of impaired transcription termination for the expansion of RNA species that may favor cancer progression. Nevertheless, future studies should provide direct evidence that a chimeric transcript has oncogenic functions in order to support the physiological relevance of these RNAs. This is a challenging and very exciting topic and further efforts are required to fully elucidate the impact of impaired transcription termination on cancer in general and on ccRCC in particular.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell culture</title><p>ccRCC cells (Caki-1, Caki-2, MF, ER, AB and FG2, Cell Line Services Eppelheim, Germany) were grown as monolayers in Dulbecco’s modified Eagle medium (DMEM, Invitrogen, CA, USA), supplemented with 10% (v/v) FBS, 1% (v/v) nonessential amino acids, 1% (v/v) L-glutamine and 100U/ml penicillin-streptomycin, and maintained at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>.</p></sec><sec id="s4-2"><title>RNA interference</title><p>RNAi was achieved using synthetic siRNA duplexes (Eurogentec, Belgium). The sequence of the siRNAs is shown in <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1I</xref>. siRNAs targeting the firefly luciferase (GL2) were used as controls. Cells were reverse transfected with 10 μM siRNAs using OptiMEM (Invitrogen) and Lipofectamine RNAiMAX (Invitrogen), according to the manufacturer’s instructions. 24 hr after the first transfection, cells were re-transfected with the same siRNA duplexes and transfection reagents and harvested on the following day.</p></sec><sec id="s4-3"><title>RNA isolation and quantitative RT–PCR</title><p>Total RNA was extracted with TRIzol (Invitrogen). cDNA was made using Superscript II Reverse Transcriptase (Invitrogen). RT-qPCR was performed in the ViiA Real Time PCR (Applied Biosystems, CA, USA), using SYBR Green PCR master mix (Applied Biosystems). The relative RNA expression was estimated as follows: 2^(Ct reference – Ct sample), where Ct reference and Ct sample are mean threshold cycles of RT-qPCR done in duplicate on cDNA samples from <italic>U6 snRNA</italic> (reference) and the cDNA from the genes of interest (sample). All primer sequences are presented in <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1I</xref>.</p></sec><sec id="s4-4"><title>Chromatin immunoprecipitation</title><p>ChIP was performed as described (<xref ref-type="bibr" rid="bib5">de Almeida et al., 2011</xref>). The relative occupancy of RNAPII at each locus was estimated by RT-qPCR as follows: 2^(Ct Input – Ct IP), where Ct Input and Ct IP are mean threshold cycles of RT-qPCR done in duplicate on DNA samples from input and specific immunoprecipitations, respectively. RNAPII was precipitated with an antibody against its largest subunit (N20, sc-899; Santa Cruz, TX, USA). The sequences of gene-specific, intergenic regions and gene desert primer pairs are presented in <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1I</xref>.</p></sec><sec id="s4-5"><title>RNA fluorescence in situ hybridization (FISH)</title><p>FG2 ccRCC cells were transiently transfected with a wt <italic>SETD2-GFP</italic> expression plasmid (<xref ref-type="bibr" rid="bib2">Carvalho et al., 2014</xref>) and cultured on glass coverslip for 24 hr before hybridization with RNA FISH probes (Biosearch Technologies, CA, USA) following the manufacturer’s protocol. Briefly, cells were washed with PBS, fixed for 10 min at room temperature, washed twice with PBS, and permeabilized at 4°C in 70% (vol/vol) EtOH. Probes diluted in hybridization buffer were added to permeabilized cells before overnight incubation in a dark chamber at 37°C. After washing, DAPI was added to stain the nuclei. Epi-fluorescence microscopy was performed using a Zeiss Z1 microscope equipped with Z-piezo (Prior, MA, USA), a 63x 1.4 NA Plan-Apochromat objective and a sCMOS camera (Hamamatsu Flash 4.0). FISH probes were designed to target a segment of the RNA transcript encoded by the intergenic region downstream of the canonical termination sites of <italic>MRPL23</italic> and <italic>SEL1L3</italic>. The sequences of the probes are shown in <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1J</xref>.</p></sec><sec id="s4-6"><title>RNA-seq datasets and preprocessing</title><p>Samples were barcoded and prepared for sequencing by the Centro Nacional de Análisis Genómico (CNAG, Barcelona, Spain) using Illumina protocols. PolyA+ RNA-seq libraries of ccRCC cell lines were sequenced as paired-end 75-bp sequence tags using the standard Illumina pipeline. ccRCC RNA-seq datasets (with at least 40 million mapped reads on each tumor and matched normal samples – in a total of 50 paired-samples listed in <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1A</xref>) were obtained from TCGA. HEK293 RNA-seq data were from the Sequence Read Archive (SRX876600). RNA-seq data from <italic>SETD2</italic> KO ccRCC cells (786-O), <italic>SETD2</italic>-depleted human MS cells and <italic>Setd2</italic> KO mouse ES cells were obtained from the GEO (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</ext-link> GSE66879, GSE19373 and GSE54932, respectively). Data quality was assessed with the FastQC (<ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>) quality-control tool for high throughput sequence data. Sequence tags were then mapped to the reference human (hg19) or mouse (mm9) genomes with TopHat software using default parameters (<xref ref-type="bibr" rid="bib13">Kim et al., 2013</xref>). Reads from samples with multiple sequencing lanes were merged and only the best score alignment was accepted for each read.</p></sec><sec id="s4-7"><title>Transcriptome alterations</title><p>Gene annotations were obtained from UCSC knownGene and refGene tables (<xref ref-type="bibr" rid="bib12">Karolchik et al., 2014</xref>) and merged into a single transcript model per gene using BedTools (<xref ref-type="bibr" rid="bib21">Quinlan and Hall, 2010</xref>). Our analysis was restricted to transcriptionally active genes defined as those with expression levels higher than the 25th percentile. To identify genes with transcriptional read-through, we filtered out all genes for which there was another annotated gene in either strand within a region of 5 Kb downstream of their TTS. We also filtered out genes with an overall increase in expression level relative to the control sample. Reads were counted in 100 bp windows for the 4 Kb region downstream of the TTS and normalized for the total number of mapped reads on each sample (RPKMs) (<xref ref-type="bibr" rid="bib18">Mortazavi et al., 2008</xref>). We considered the occurrence of transcriptional read-through when more than six 100 bp windows showed increased (at least 1.5 fold-change) RPKMs relative to control. The control samples were: Caki2 for ccRCC cell lines; the matched normal tissue sample for each ccRCC patient; control 786-O ccRCC cells for <italic>SETD2</italic> KO 786-O cells; human MS cells for <italic>SETD2</italic>-depleted human MS cells; and wt mouse ES cells for the <italic>Setd2</italic> KO mouse. In the ccRCC cell lines dataset, all the analysis were also performed comparing both <italic>SETD2</italic> wt (Caki1 vs Caki2), with this comparison working as a negative control. Statistical significance of the differences between proportions of genes showing read-through was assessed using the Fisher’s exact test. RNA chimeras were detected using the fusion-search option (fusion-min-dist set to 100 bp) in TopHat alignment (<xref ref-type="bibr" rid="bib13">Kim et al., 2013</xref>) and TopHat-Fusion (<xref ref-type="bibr" rid="bib14">Kim and Salzberg, 2011</xref>) with default parameters. For downstream analysis we only considered RNA chimeras supported by at least two reads. A set of in-house scripts were written in bash and in the R environmental language (<ext-link ext-link-type="uri" xlink:href="http://www.R-project.org/">http://www.R-project.org/</ext-link>) (<xref ref-type="bibr" rid="bib22">Team RDC, 2011</xref>).</p></sec><sec id="s4-8"><title>Graphical representation of data</title><p>Figures were produced using BedTools (<xref ref-type="bibr" rid="bib21">Quinlan and Hall, 2010</xref>) and default packages from the R environment. To produce heatmaps and metagene average profiles showing transcription read-through, genes were scaled to 60 equally sized bins so that all annotated TSSs and TTSs were aligned. Regions 4 Kb upstream of TSSs and 4 Kb downstream of TTSs were averaged in a 100-bp window. Individual gene profiles were produced by successions of 10-bp windows (single gene) or 100-bp windows (two genes). All read counts were normalized by genomic region length and number of mapped reads (RPKM), and RPKM values were log2 transformed when representing multiple genes. Protein levels assessed by reverse phase protein array (RPPA) were gathered from the TCGA portal. Circle plots showing RNA chimeras distribution were produced using Circos (<xref ref-type="bibr" rid="bib15">Krzywinski et al., 2009</xref>).</p></sec><sec id="s4-9"><title>Accession codes for RNA-seq data</title><p>The RNA-seq data for ccRCC cell lines have been deposited in Gene Expression Omnibus (GEO; <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</ext-link>) database under the accession number GSE64451. ccRCC RNA-seq datasets were obtained from TCGA. HEK293 RNA-seq data were from the Sequence Read Archive (SRX876600). RNA-seq data from <italic>SETD2</italic> KO 786-O ccRCC cells, human mesenchymal stem cells and mouse embryonic stem cells were obtained from the GEO (GSE66879, GSE19373 and GSE54932, respectively).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank our colleagues Nuno Barbosa-Morais, Sérgio Dias and Edgar Gomes for critical comments and suggestions. We also thank Ioana Posa, Mafalda Pimentel, Célia Carvalho and the Bioimaging Unit of the IMM for technical assistance. This work was supported by Fundação para a Ciência e Tecnologia (FCT), Portugal (PTDC/BIM-ONC/0384-2012 to SFdA). MRM is a FCT PhD fellow (SFRH/BD/92208/2013). ACV is a Lisbon BioMed PhD fellow funded by FCT (SFRH/BD/52232/2013). ARG is the recipient of a FCT Investigator award (IF/00510/2014).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>ARG, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>APL, Conception and design, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con3"><p>SC, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con4"><p>MRM, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con5"><p>FBM, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con6"><p>ACV, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con7"><p>JMPD, Acquisition of data, Analysis and interpretation of data, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con8"><p>MCF, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con9"><p>SFDA, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.09214.014</object-id><label>Supplementary file 1.</label><caption><p>(<bold>A</bold>) Genes with transcription read-through identified in human ccRCC TCGA samples. (<bold>B</bold>) Genes involved in transcription termination and pre-mRNA processing with mutations in TCGA samples. (<bold>C</bold>) Genes with transcription read-through identified in human ccRCC cell lines. (<bold>D</bold>) Genes with transcription read-through identified in human 786-O ccRCC cells. (<bold>E</bold>) Genes with transcription read-through identified in human mesenchymal stem cells. (<bold>F</bold>) Genes with transcription read-through identified in mouse embryonic stem cells. (<bold>G</bold>) Genes with transcription read-through identified in human ccRCC TCGA samples, showing significant correlation between read-through levels and expression of downstream gene. (<bold>H</bold>). Read-Through RNA chimeras identified in human ccRCC TCGA samples and ccRCC cell lines. (<bold>I</bold>). siRNAs and Primer Sequences. (<bold>J</bold>) Sequences of RNA FISH probes.</p> <p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09214.014">http://dx.doi.org/10.7554/eLife.09214.014</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-09214-supp1-v2.xlsx"/></supplementary-material><sec id="s7" sec-type="datasets"><title>Major datasets</title><p>The following datasets were generated:</p> <p><related-object content-type="generated-dataset" id="dataro1" source-id="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64451" source-id-type="uri"><collab>Grosso AR</collab>, <collab>Leite AP</collab>, <collab>Carvalho S</collab>, <collab>Matos M</collab>, <collab>Martins FB</collab>, <collab>Vitor AC</collab>, <collab>Desterro J</collab>, <collab>Carmo-Fonseca M</collab>, <collab>de Almeida SF</collab><x>,</x> <year>2015</year><x>,</x><source>Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64451">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64451</ext-link><x>,</x> <comment>Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSE64451).</comment></related-object></p> <p>The following previously published datasets were used:</p> <p><related-object content-type="generated-dataset" id="dataro2" source-id="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19373" source-id-type="uri"><collab>Luco RF</collab>, <collab>Pan Q</collab>, <collab>Tominaga K</collab>, <collab>Blencowe BJ</collab>, <collab>Pereira-Smith OM</collab>, <collab>Misteli T</collab><x>,</x> <year>2010</year><x>,</x><source>Regulation of alternative splicing by histone modifications</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19373">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19373</ext-link><x>,</x> <comment>Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSE19373).</comment></related-object></p> <p><related-object content-type="generated-dataset" id="dataro3" source-id="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54932" source-id-type="uri"><collab>Zhang Y</collab>, <collab>Chen Z</collab>, <collab>Huang Q</collab>, <collab>Chen S</collab><x>,</x> <year>2014</year><x>,</x><source>Quantitative Analysis of Wild Type(wt) and Setd2 knockout(ko) mESCs Transcriptomes [RNA-Seq]</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54932">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54932</ext-link><x>,</x> <comment>Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSE54932).</comment></related-object></p> <p><related-object content-type="generated-dataset" id="dataro4" source-id="http://www.ncbi.nlm.nih.gov/sra/?term=SRX876600" source-id-type="uri"><collab>Memorial Sloan Kettering Cancer Center</collab><x>,</x> <year>2015</year><x>,</x><source>RNA-seq of HEK293 with empty vector (replicate 2)</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/sra/?term=SRX876600">http://www.ncbi.nlm.nih.gov/sra/?term=SRX876600</ext-link><x>,</x> <comment>Publicly available at the NCBI Short Read Archive (Accession no: SRX876600).</comment></related-object></p> <p><related-object content-type="generated-dataset" id="dataro5" source-id="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66879" source-id-type="uri"><collab>Ho TH</collab>, <collab>Nie J</collab>, <collab>Yan H</collab><x>,</x> <year>2015</year><x>,</x><source>RNA sequencing of SETD2 isogenic renal cell carcinoma cell lines</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66879">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66879</ext-link><x>,</x> <comment>Publicly available at the NCBI Gene Expression Omnibus (Accession no: GSE66879).</comment></related-object></p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research N</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Comprehensive molecular characterization of clear cell renal cell carcinoma</article-title><source>Nature</source><volume>499</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1038/nature12222</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>S</given-names></name><name><surname>Vítor</surname><given-names>AC</given-names></name><name><surname>Sridhara</surname><given-names>SC</given-names></name><name><surname>Martins</surname><given-names>FB</given-names></name><name><surname>Raposo</surname><given-names>AC</given-names></name><name><surname>Desterro</surname><given-names>JMP</given-names></name><name><surname>Ferreira</surname><given-names>J</given-names></name><name><surname>de Almeida</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint</article-title><source>eLife</source><volume>3</volume><elocation-id>e02482</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.02482</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Morgan</surname><given-names>M</given-names></name><name><surname>Gunaratne</surname><given-names>PH</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Gordon Robertson</surname><given-names>A</given-names></name><name><surname>Chu</surname><given-names>A</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Signoretti</surname><given-names>S</given-names></name><name><surname>Vandin Hsin-Ta Wu</surname><given-names>F</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name><name><surname>Verhaak</surname><given-names>RGW</given-names></name><name><surname>Tamboli</surname><given-names>P</given-names></name><name><surname>Torres-Garcia</surname><given-names>W</given-names></name><name><surname>Akbani</surname><given-names>R</given-names></name><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Reuter</surname><given-names>V</given-names></name><name><surname>Hsieh</surname><given-names>JJ</given-names></name><name><surname>Rose Brannon</surname><given-names>A</given-names></name><name><surname>Ari Hakimi</surname><given-names>A</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Ciriello</surname><given-names>G</given-names></name><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Ricketts</surname><given-names>CJ</given-names></name><name><surname>Marston Linehan</surname><given-names>W</given-names></name><name><surname>Stuart</surname><given-names>JM</given-names></name><name><surname>Kimryn Rathmell</surname><given-names>W</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Laird</surname><given-names>PW</given-names></name><name><surname>Muzny</surname><given-names>D</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><name><surname>Morgan</surname><given-names>M</given-names></name><name><surname>Xi</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>K</given-names></name><name><surname>Kakkar</surname><given-names>N</given-names></name><name><surname>Treviño</surname><given-names>LR</given-names></name><name><surname>Benton</surname><given-names>S</given-names></name><name><surname>Reid</surname><given-names>JG</given-names></name><name><surname>Morton</surname><given-names>D</given-names></name><name><surname>Doddapaneni</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Lewis</surname><given-names>L</given-names></name><name><surname>Dinh</surname><given-names>H</given-names></name><name><surname>Kovar</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Santibanez</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Hale</surname><given-names>W</given-names></name><name><surname>Kalra</surname><given-names>D</given-names></name><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Sivachenko</surname><given-names>A</given-names></name><name><surname>Lichtenstein</surname><given-names>L</given-names></name><name><surname>Stewart</surname><given-names>C</given-names></name><name><surname>Voet</surname><given-names>D</given-names></name><name><surname>Fisher</surname><given-names> Sheila</given-names></name><name><surname>Gabriel</surname><given-names> Stacey B.</given-names></name><name><surname>Lander</surname><given-names>E</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Schumacher</surname><given-names> Steve E.</given-names></name><name><surname>Tabak</surname><given-names>B</given-names></name><name><surname>Saksena</surname><given-names> Gordon</given-names></name><name><surname>Onofrio</surname><given-names>RC</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><name><surname>Gentry</surname><given-names> Jeff</given-names></name><name><surname>Ardlie</surname><given-names>K</given-names></name><name><surname>Sougnez</surname><given-names> Carrie</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Gordon Robertson</surname><given-names>A</given-names></name><name><surname>Chu</surname><given-names>A</given-names></name><name><surname>Chun</surname><given-names>H-JE</given-names></name><name><surname>Mungall</surname><given-names>AJ</given-names></name><name><surname>Sipahimalani</surname><given-names>P</given-names></name><name><surname>Stoll</surname><given-names>D</given-names></name><name><surname>Ally</surname><given-names>A</given-names></name><name><surname>Balasundaram</surname><given-names>M</given-names></name><name><surname>Butterfield</surname><given-names>YSN</given-names></name><name><surname>Carlsen</surname><given-names>R</given-names></name><name><surname>Carter</surname><given-names>C</given-names></name><name><surname>Chuah</surname><given-names>E</given-names></name><name><surname>Coope</surname><given-names>RJN</given-names></name><name><surname>Dhalla</surname><given-names>N</given-names></name><name><surname>Gorski</surname><given-names>S</given-names></name><name><surname>Guin</surname><given-names>R</given-names></name><name><surname>Hirst</surname><given-names>C</given-names></name><name><surname>Hirst</surname><given-names>M</given-names></name><name><surname>Holt</surname><given-names>RA</given-names></name><name><surname>Lebovitz</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>HI</given-names></name><name><surname>Mayo</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>RA</given-names></name><name><surname>Pleasance</surname><given-names>E</given-names></name><name><surname>Plettner</surname><given-names>P</given-names></name><name><surname>Schein</surname><given-names>JE</given-names></name><name><surname>Shafiei</surname><given-names>A</given-names></name><name><surname>Slobodan</surname><given-names>JR</given-names></name><name><surname>Tam</surname><given-names>A</given-names></name><name><surname>Thiessen</surname><given-names>N</given-names></name><name><surname>Varhol</surname><given-names>RJ</given-names></name><name><surname>Wye</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Birol</surname><given-names>I</given-names></name><name><surname>Jones</surname><given-names>SJM</given-names></name><name><surname>Marra</surname><given-names>MA</given-names></name><name><surname>Auman</surname><given-names>JT</given-names></name><name><surname>Tan</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>CD</given-names></name><name><surname>Hoadley</surname><given-names>KA</given-names></name><name><surname>Mieczkowski</surname><given-names>PA</given-names></name><name><surname>Mose</surname><given-names>LE</given-names></name><name><surname>Jefferys</surname><given-names>SR</given-names></name><name><surname>Topal</surname><given-names>MD</given-names></name><name><surname>Liquori</surname><given-names>C</given-names></name><name><surname>Turman</surname><given-names>YJ</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Waring</surname><given-names>S</given-names></name><name><surname>Buda</surname><given-names>E</given-names></name><name><surname>Walsh</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Bodenheimer</surname><given-names>T</given-names></name><name><surname>Hoyle</surname><given-names>AP</given-names></name><name><surname>Simons</surname><given-names>JV</given-names></name><name><surname>Soloway</surname><given-names>MG</given-names></name><name><surname>Balu</surname><given-names>S</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Neil Hayes</surname><given-names>D</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Kucherlapati</surname><given-names>R</given-names></name><name><surname>Park</surname><given-names>P</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Triche Jr</surname><given-names>T</given-names></name><name><surname>Weisenberger</surname><given-names>DJ</given-names></name><name><surname>Lai</surname><given-names>PH</given-names></name><name><surname>Bootwalla</surname><given-names>MS</given-names></name><name><surname>Maglinte</surname><given-names>DT</given-names></name><name><surname>Mahurkar</surname><given-names>S</given-names></name><name><surname>Berman</surname><given-names>BP</given-names></name><name><surname>Van Den Berg</surname><given-names>DJ</given-names></name><name><surname>Cope</surname><given-names>L</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Laird</surname><given-names>PW</given-names></name><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Noble</surname><given-names>MS</given-names></name><name><surname>DiCara</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Heiman</surname><given-names>DI</given-names></name><name><surname>Gehlenborg</surname><given-names>N</given-names></name><name><surname>Voet</surname><given-names>D</given-names></name><name><surname>Mallard</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Frazer</surname><given-names>S</given-names></name><name><surname>Stojanov</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Vandin</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>H-T</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name><name><surname>Benz</surname><given-names>C</given-names></name><name><surname>Yau</surname><given-names>C</given-names></name><name><surname>Reynolds</surname><given-names>SM</given-names></name><name><surname>Shmulevich</surname><given-names>I</given-names></name><name><surname>Verhaak</surname><given-names>RGW</given-names></name><name><surname>Torres-Garcia</surname><given-names>W</given-names></name><name><surname>Vegesna</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Cogdell</surname><given-names>D</given-names></name><name><surname>Jonasch</surname><given-names>E</given-names></name><name><surname>Ding</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Akbani</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Unruh</surname><given-names>AK</given-names></name><name><surname>Casasent</surname><given-names>TD</given-names></name><name><surname>Wakefield</surname><given-names>C</given-names></name><name><surname>Tsavachidou</surname><given-names>D</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Rose Brannon</surname><given-names>A</given-names></name><name><surname>Ciriello</surname><given-names>G</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Ari Hakimi</surname><given-names>A</given-names></name><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Antipin</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gross</surname><given-names>B</given-names></name><name><surname>Arman Aksoy</surname><given-names>B</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Weinhold</surname><given-names>N</given-names></name><name><surname>Onur Sumer</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Ostrovnaya</surname><given-names>I</given-names></name><name><surname>Hsieh</surname><given-names>JJ</given-names></name><name><surname>Berger</surname><given-names>MF</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Fei</surname><given-names>SS</given-names></name><name><surname>Stout</surname><given-names>A</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Rubin</surname><given-names>DL</given-names></name><name><surname>Liu</surname><given-names>TT</given-names></name><name><surname>Stuart</surname><given-names>JM</given-names></name><name><surname>Ng</surname><given-names>S</given-names></name><name><surname>Paull</surname><given-names>EO</given-names></name><name><surname>Carlin</surname><given-names>D</given-names></name><name><surname>Goldstein</surname><given-names>T</given-names></name><name><surname>Waltman</surname><given-names>P</given-names></name><name><surname>Ellrott</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name><name><surname>Gunaratne</surname><given-names>PH</given-names></name><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Shelton</surname><given-names>C</given-names></name><name><surname>Gardner</surname><given-names>J</given-names></name><name><surname>Penny</surname><given-names>R</given-names></name><name><surname>Sherman</surname><given-names>M</given-names></name><name><surname>Mallery</surname><given-names>D</given-names></name><name><surname>Morris</surname><given-names>S</given-names></name><name><surname>Paulauskis</surname><given-names>J</given-names></name><name><surname>Burnett</surname><given-names>K</given-names></name><name><surname>Shelton</surname><given-names>T</given-names></name><name><surname>Signoretti</surname><given-names>S</given-names></name><name><surname>Kaelin</surname><given-names>WG</given-names></name><name><surname>Choueiri</surname><given-names>T</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name><name><surname>Penny</surname><given-names>R</given-names></name><name><surname>Burnett</surname><given-names>K</given-names></name><name><surname>Mallery</surname><given-names>D</given-names></name><name><surname>Curley</surname><given-names>E</given-names></name><name><surname>Tickoo</surname><given-names>S</given-names></name><name><surname>Reuter</surname><given-names>V</given-names></name><name><surname>Kimryn Rathmell</surname><given-names>W</given-names></name><name><surname>Thorne</surname><given-names>L</given-names></name><name><surname>Boice</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Fisher</surname><given-names>JC</given-names></name><name><surname>Marston Linehan</surname><given-names>W</given-names></name><name><surname>Vocke</surname><given-names>CD</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><name><surname>Worrell</surname><given-names>R</given-names></name><name><surname>Merino</surname><given-names>MJ</given-names></name><name><surname>Schmidt</surname><given-names>LS</given-names></name><name><surname>Tamboli</surname><given-names>P</given-names></name><name><surname>Czerniak</surname><given-names>BA</given-names></name><name><surname>Aldape</surname><given-names>KD</given-names></name><name><surname>Wood</surname><given-names>CG</given-names></name><name><surname>Boyd</surname><given-names>J</given-names></name><name><surname>Weaver</surname><given-names>J</given-names></name><name><surname>Iacocca</surname><given-names>MV</given-names></name><name><surname>Petrelli</surname><given-names>N</given-names></name><name><surname>Witkin</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Czerwinski</surname><given-names>C</given-names></name><name><surname>Huelsenbeck-Dill</surname><given-names>L</given-names></name><name><surname>Rabeno</surname><given-names>B</given-names></name><name><surname>Myers</surname><given-names>J</given-names></name><name><surname>Morrison</surname><given-names>C</given-names></name><name><surname>Bergsten</surname><given-names>J</given-names></name><name><surname>Eckman</surname><given-names>J</given-names></name><name><surname>Harr</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Tucker</surname><given-names>K</given-names></name><name><surname>Anne Zach</surname><given-names>L</given-names></name><name><surname>Bshara</surname><given-names>W</given-names></name><name><surname>Gaudioso</surname><given-names>C</given-names></name><name><surname>Morrison</surname><given-names>C</given-names></name><name><surname>Dhir</surname><given-names>R</given-names></name><name><surname>Maranchie</surname><given-names>J</given-names></name><name><surname>Nelson</surname><given-names>J</given-names></name><name><surname>Parwani</surname><given-names>A</given-names></name><name><surname>Potapova</surname><given-names>O</given-names></name><name><surname>Fedosenko</surname><given-names>K</given-names></name><name><surname>Cheville</surname><given-names>JC</given-names></name><name><surname>Houston Thompson</surname><given-names>R</given-names></name><name><surname>Signoretti</surname><given-names>S</given-names></name><name><surname>Kaelin</surname><given-names>WG</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name><name><surname>Tickoo</surname><given-names>S</given-names></name><name><surname>Reuter</surname><given-names>V</given-names></name><name><surname>Marston Linehan</surname><given-names>W</given-names></name><name><surname>Vocke</surname><given-names>CD</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><name><surname>Merino</surname><given-names>MJ</given-names></name><name><surname>Schmidt</surname><given-names>LS</given-names></name><name><surname>Tamboli</surname><given-names>P</given-names></name><name><surname>Mosquera</surname><given-names>JM</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Blute</surname><given-names>ML</given-names></name><name><surname>Kimryn Rathmell</surname><given-names>W</given-names></name><name><surname>Pihl</surname><given-names>T</given-names></name><name><surname>Jensen</surname><given-names>M</given-names></name><name><surname>Sfeir</surname><given-names>R</given-names></name><name><surname>Kahn</surname><given-names>A</given-names></name><name><surname>Chu</surname><given-names>A</given-names></name><name><surname>Kothiyal</surname><given-names>P</given-names></name><name><surname>Snyder</surname><given-names>E</given-names></name><name><surname>Pontius</surname><given-names>J</given-names></name><name><surname>Ayala</surname><given-names>B</given-names></name><name><surname>Backus</surname><given-names>M</given-names></name><name><surname>Walton</surname><given-names>J</given-names></name><name><surname>Baboud</surname><given-names>J</given-names></name><name><surname>Berton</surname><given-names>D</given-names></name><name><surname>Nicholls</surname><given-names>M</given-names></name><name><surname>Srinivasan</surname><given-names>D</given-names></name><name><surname>Raman</surname><given-names>R</given-names></name><name><surname>Girshik</surname><given-names>S</given-names></name><name><surname>Kigonya</surname><given-names>P</given-names></name><name><surname>Alonso</surname><given-names>S</given-names></name><name><surname>Sanbhadti</surname><given-names>R</given-names></name><name><surname>Barletta</surname><given-names>S</given-names></name><name><surname>Pot</surname><given-names>D</given-names></name><name><surname>Sheth</surname><given-names>M</given-names></name><name><surname>Demchok</surname><given-names>JA</given-names></name><name><surname>Davidsen</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Tarnuzzer</surname><given-names>RW</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Eley</surname><given-names>G</given-names></name><name><surname>Ferguson</surname><given-names>ML</given-names></name><name><surname>Mills Shaw</surname><given-names>KR</given-names></name><name><surname>Guyer</surname><given-names>MS</given-names></name><name><surname>Ozenberger</surname><given-names>BA</given-names></name><name><surname>Sofia.</surname><given-names>HJ</given-names></name><collab>The Cancer Genome Atlas Research Network AwgBCoM</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Comprehensive molecular characterization of clear cell renal cell carcinoma</article-title><source>Nature</source><volume>499</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1038/nature12222</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalgliesh</surname><given-names>GL</given-names></name><name><surname>Furge</surname><given-names>K</given-names></name><name><surname>Greenman</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Bignell</surname><given-names>G</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Edkins</surname><given-names>S</given-names></name><name><surname>Hardy</surname><given-names>C</given-names></name><name><surname>Latimer</surname><given-names>C</given-names></name><name><surname>Teague</surname><given-names>J</given-names></name><name><surname>Andrews</surname><given-names>J</given-names></name><name><surname>Barthorpe</surname><given-names>S</given-names></name><name><surname>Beare</surname><given-names>D</given-names></name><name><surname>Buck</surname><given-names>G</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Forbes</surname><given-names>S</given-names></name><name><surname>Jia</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Knott</surname><given-names>H</given-names></name><name><surname>Kok</surname><given-names>CY</given-names></name><name><surname>Lau</surname><given-names>KW</given-names></name><name><surname>Leroy</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>M-L</given-names></name><name><surname>McBride</surname><given-names>DJ</given-names></name><name><surname>Maddison</surname><given-names>M</given-names></name><name><surname>Maguire</surname><given-names>S</given-names></name><name><surname>McLay</surname><given-names>K</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Mironenko</surname><given-names>T</given-names></name><name><surname>Mulderrig</surname><given-names>L</given-names></name><name><surname>Mudie</surname><given-names>L</given-names></name><name><surname>O’Meara</surname><given-names>S</given-names></name><name><surname>Pleasance</surname><given-names>E</given-names></name><name><surname>Rajasingham</surname><given-names>A</given-names></name><name><surname>Shepherd</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Stebbings</surname><given-names>L</given-names></name><name><surname>Stephens</surname><given-names>P</given-names></name><name><surname>Tang</surname><given-names>G</given-names></name><name><surname>Tarpey</surname><given-names>PS</given-names></name><name><surname>Turrell</surname><given-names>K</given-names></name><name><surname>Dykema</surname><given-names>KJ</given-names></name><name><surname>Khoo</surname><given-names>SK</given-names></name><name><surname>Petillo</surname><given-names>D</given-names></name><name><surname>Wondergem</surname><given-names>B</given-names></name><name><surname>Anema</surname><given-names>J</given-names></name><name><surname>Kahnoski</surname><given-names>RJ</given-names></name><name><surname>Teh</surname><given-names>BT</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes</article-title><source>Nature</source><volume>463</volume><fpage>360</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1038/nature08672</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Almeida</surname><given-names>SF</given-names></name><name><surname>Grosso</surname><given-names>AR</given-names></name><name><surname>Koch</surname><given-names>F</given-names></name><name><surname>Fenouil</surname><given-names>R</given-names></name><name><surname>Carvalho</surname><given-names>S</given-names></name><name><surname>Andrade</surname><given-names>J</given-names></name><name><surname>Levezinho</surname><given-names>H</given-names></name><name><surname>Gut</surname><given-names>M</given-names></name><name><surname>Eick</surname><given-names>D</given-names></name><name><surname>Gut</surname><given-names>I</given-names></name><name><surname>Andrau</surname><given-names>J-C</given-names></name><name><surname>Ferrier</surname><given-names>P</given-names></name><name><surname>Carmo-Fonseca</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>18</volume><fpage>977</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2123</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duns</surname><given-names>G</given-names></name><name><surname>van den Berg</surname><given-names>E</given-names></name><name><surname>van Duivenbode</surname><given-names>I</given-names></name><name><surname>Osinga</surname><given-names>J</given-names></name><name><surname>Hollema</surname><given-names>H</given-names></name><name><surname>Hofstra</surname><given-names>RMW</given-names></name><name><surname>Kok</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma</article-title><source>Cancer Research</source><volume>70</volume><fpage>4287</fpage><lpage>4291</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0120</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dye</surname><given-names>MJ</given-names></name><name><surname>Proudfoot</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Terminal exon definition occurs cotranscriptionally and promotes termination of RNA polymerase II</article-title><source>Molecular Cell</source><volume>3</volume><fpage>371</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(00)80464-5</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Implications of chimaeric non-co-linear transcripts</article-title><source>Nature</source><volume>461</volume><fpage>206</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1038/nature08452</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgs</surname><given-names>DR</given-names></name><name><surname>Goodbourn</surname><given-names>SEY</given-names></name><name><surname>Lamb</surname><given-names>J</given-names></name><name><surname>Clegg</surname><given-names>JB</given-names></name><name><surname>Weatherall</surname><given-names>DJ</given-names></name><name><surname>Proudfoot</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>α-thalassaemia caused by a polyadenylation signal mutation</article-title><source>Nature</source><volume>306</volume><fpage>398</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1038/306398a0</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>TH</given-names></name><name><surname>Park</surname><given-names>IY</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Tong</surname><given-names>P</given-names></name><name><surname>Champion</surname><given-names>MD</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Monzon</surname><given-names>FA</given-names></name><name><surname>Hoang</surname><given-names>A</given-names></name><name><surname>Tamboli</surname><given-names>P</given-names></name><name><surname>Parker</surname><given-names>AS</given-names></name><name><surname>Joseph</surname><given-names>RW</given-names></name><name><surname>Qiao</surname><given-names>W</given-names></name><name><surname>Dykema</surname><given-names>K</given-names></name><name><surname>Tannir</surname><given-names>NM</given-names></name><name><surname>Castle</surname><given-names>EP</given-names></name><name><surname>Nunez-Nateras</surname><given-names>R</given-names></name><name><surname>Teh</surname><given-names>BT</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Walker</surname><given-names>CL</given-names></name><name><surname>Hung</surname><given-names>M-C</given-names></name><name><surname>Jonasch</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma</article-title><source>Oncogene</source><pub-id pub-id-type="doi">10.1038/onc.2015.221</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandoth</surname><given-names>C</given-names></name><name><surname>McLellan</surname><given-names>MD</given-names></name><name><surname>Vandin</surname><given-names>F</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Niu</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>McMichael</surname><given-names>JF</given-names></name><name><surname>Wyczalkowski</surname><given-names>MA</given-names></name><name><surname>Leiserson</surname><given-names>MDM</given-names></name><name><surname>Miller</surname><given-names>CA</given-names></name><name><surname>Welch</surname><given-names>JS</given-names></name><name><surname>Walter</surname><given-names>MJ</given-names></name><name><surname>Wendl</surname><given-names>MC</given-names></name><name><surname>Ley</surname><given-names>TJ</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mutational landscape and significance across 12 major cancer types</article-title><source>Nature</source><volume>502</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/nature12634</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karolchik</surname><given-names>D</given-names></name><name><surname>Barber</surname><given-names>GP</given-names></name><name><surname>Casper</surname><given-names>J</given-names></name><name><surname>Clawson</surname><given-names>H</given-names></name><name><surname>Cline</surname><given-names>MS</given-names></name><name><surname>Diekhans</surname><given-names>M</given-names></name><name><surname>Dreszer</surname><given-names>TR</given-names></name><name><surname>Fujita</surname><given-names>PA</given-names></name><name><surname>Guruvadoo</surname><given-names>L</given-names></name><name><surname>Haeussler</surname><given-names>M</given-names></name><name><surname>Harte</surname><given-names>RA</given-names></name><name><surname>Heitner</surname><given-names>S</given-names></name><name><surname>Hinrichs</surname><given-names>AS</given-names></name><name><surname>Learned</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>BT</given-names></name><name><surname>Li</surname><given-names>CH</given-names></name><name><surname>Raney</surname><given-names>BJ</given-names></name><name><surname>Rhead</surname><given-names>B</given-names></name><name><surname>Rosenbloom</surname><given-names>KR</given-names></name><name><surname>Sloan</surname><given-names>CA</given-names></name><name><surname>Speir</surname><given-names>ML</given-names></name><name><surname>Zweig</surname><given-names>AS</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name><name><surname>Kuhn</surname><given-names>RM</given-names></name><name><surname>Kent</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The UCSC genome browser database: 2014 update</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>D764</fpage><lpage>D770</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1168</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Pertea</surname><given-names>G</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pimentel</surname><given-names>H</given-names></name><name><surname>Kelley</surname><given-names>R</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions</article-title><source>Genome Biology</source><volume>14</volume><fpage>R36</fpage><pub-id pub-id-type="doi">10.1186/gb-2013-14-4-r36</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>TopHat-fusion: an algorithm for discovery of novel fusion transcripts</article-title><source>Genome Biology</source><volume>12</volume><fpage>R72</fpage><pub-id pub-id-type="doi">10.1186/gb-2011-12-8-r72</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krzywinski</surname><given-names>M</given-names></name><name><surname>Schein</surname><given-names>J</given-names></name><name><surname>Birol</surname><given-names>I</given-names></name><name><surname>Connors</surname><given-names>J</given-names></name><name><surname>Gascoyne</surname><given-names>R</given-names></name><name><surname>Horsman</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>SJ</given-names></name><name><surname>Marra</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Circos: an information aesthetic for comparative genomics</article-title><source>Genome Research</source><volume>19</volume><fpage>1639</fpage><lpage>1645</lpage><pub-id pub-id-type="doi">10.1101/gr.092759.109</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuehner</surname><given-names>JN</given-names></name><name><surname>Pearson</surname><given-names>EL</given-names></name><name><surname>Moore</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Unravelling the means to an end: RNA polymerase II transcription termination</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>12</volume><fpage>283</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1038/nrm3098</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luco</surname><given-names>RF</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Tominaga</surname><given-names>K</given-names></name><name><surname>Blencowe</surname><given-names>BJ</given-names></name><name><surname>Pereira-Smith</surname><given-names>OM</given-names></name><name><surname>Misteli</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regulation of alternative splicing by histone modifications</article-title><source>Science</source><volume>327</volume><fpage>996</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1126/science.1184208</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortazavi</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>BA</given-names></name><name><surname>McCue</surname><given-names>K</given-names></name><name><surname>Schaeffer</surname><given-names>L</given-names></name><name><surname>Wold</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Mapping and quantifying mammalian transcriptomes by RNA-seq</article-title><source>Nature Methods</source><volume>5</volume><fpage>621</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1226</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niwa</surname><given-names>M</given-names></name><name><surname>MacDonald</surname><given-names>CC</given-names></name><name><surname>Berget</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Are vertebrate exons scanned during splice-site selection?</article-title><source>Nature</source><volume>360</volume><fpage>277</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1038/360277a0</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proudfoot</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Transcriptional interference and termination between duplicated α-globin gene constructs suggests a novel mechanism for gene regulation</article-title><source>Nature</source><volume>322</volume><fpage>562</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1038/322562a0</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinlan</surname><given-names>AR</given-names></name><name><surname>Hall</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title><source>Bioinformatics</source><volume>26</volume><fpage>841</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq033</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="book"><person-group person-group-type="author"><collab>Team RDC</collab></person-group><year iso-8601-date="2011">2011</year><source>R: A Language and Environment for Statistical Computing</source><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>J-P</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Itoh</surname><given-names>I</given-names></name><name><surname>Muramoto</surname><given-names>M</given-names></name><name><surname>Hyodo</surname><given-names>T</given-names></name><name><surname>Irie</surname><given-names>A</given-names></name><name><surname>Akahoshi</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>S-X</given-names></name><name><surname>Kameya</surname><given-names>T</given-names></name><name><surname>Baba</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Antitumor effect of <italic>bcl-2</italic> antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice</article-title><source>Molecular Urology</source><volume>5</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1089/109153601300177583</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varela</surname><given-names>I</given-names></name><name><surname>Tarpey</surname><given-names>P</given-names></name><name><surname>Raine</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Ong</surname><given-names>CK</given-names></name><name><surname>Stephens</surname><given-names>P</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>M-L</given-names></name><name><surname>Teague</surname><given-names>J</given-names></name><name><surname>Bignell</surname><given-names>G</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Dalgliesh</surname><given-names>GL</given-names></name><name><surname>Galappaththige</surname><given-names>D</given-names></name><name><surname>Greenman</surname><given-names>C</given-names></name><name><surname>Hardy</surname><given-names>C</given-names></name><name><surname>Jia</surname><given-names>M</given-names></name><name><surname>Latimer</surname><given-names>C</given-names></name><name><surname>Lau</surname><given-names>KW</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><name><surname>McLaren</surname><given-names>S</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Mudie</surname><given-names>L</given-names></name><name><surname>Stebbings</surname><given-names>L</given-names></name><name><surname>Largaespada</surname><given-names>DA</given-names></name><name><surname>Wessels</surname><given-names>LFA</given-names></name><name><surname>Richard</surname><given-names>S</given-names></name><name><surname>Kahnoski</surname><given-names>RJ</given-names></name><name><surname>Anema</surname><given-names>J</given-names></name><name><surname>A.Tuveson</surname><given-names>D</given-names></name><name><surname>Perez-Mancera</surname><given-names>PA</given-names></name><name><surname>Mustonen</surname><given-names>V</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Adams</surname><given-names>DJ</given-names></name><name><surname>Rust</surname><given-names>A</given-names></name><name><surname>Chan-on</surname><given-names>W</given-names></name><name><surname>Subimerb</surname><given-names>C</given-names></name><name><surname>Dykema</surname><given-names>K</given-names></name><name><surname>Furge</surname><given-names>K</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Teh</surname><given-names>BT</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma</article-title><source>Nature</source><volume>469</volume><fpage>539</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1038/nature09639</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zack</surname><given-names>TI</given-names></name><name><surname>Schumacher</surname><given-names>SE</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><name><surname>Saksena</surname><given-names>G</given-names></name><name><surname>Tabak</surname><given-names>B</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Zhang</surname><given-names>C-Z</given-names></name><name><surname>Wala</surname><given-names>J</given-names></name><name><surname>Mermel</surname><given-names>CH</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Hernandez</surname><given-names>B</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Laird</surname><given-names>PW</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Pan-cancer patterns of somatic copy number alteration</article-title><source>Nature Genetics</source><volume>45</volume><fpage>1134</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1038/ng.2760</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>H3K36 histone methyltransferase Setd2 is required for murine embryonic stem cell differentiation toward endoderm</article-title><source>Cell Reports</source><volume>8</volume><fpage>1989</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.08.031</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.09214.025</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dang</surname><given-names>Chi Van</given-names></name><role>Reviewing editor</role><aff id="aff3"><institution>University of Pennsylvania</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see <ext-link ext-link-type="uri" xlink:href="http://elifesciences.org/review-process">review process</ext-link>). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.</p></boxed-text><p>Thank you for submitting your work entitled &quot;Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma&quot; for peer review at <italic>eLife</italic>. Your submission has been favorably evaluated by Mark McCarthy (Senior editor) and three reviewers, one of whom, Chi Dang, is a member of our Board of Reviewing Editors.</p><p>The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>The manuscript titled, &quot;Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma&quot; by Grosso et al., analyzes the transcription profiles from publically available database (TCGA) of RNA-seq results from 50 ccRCC primary samples to identify improper termination events that occur in these samples. The authors identified transcriptional read-through (TRT) events in the entire genome. While this effect is noticeable it is also subtle as summarized in <xref ref-type="fig" rid="fig1">Figure 1C</xref>. Even though the effect occurs not exclusively in those tumors where <italic>SetD2</italic> is mutated, grouping the tumor samples according to <italic>SetD2</italic> mutations shows that these have an overall higher prevalence of TRT, which also correlates with higher read numbers of the adjacent gene and occurrence of chimeric transcripts. The authors conclude that mutations in the <italic>SETD2</italic> gene, which is involved in setting H3K36 methylation along transcribed sequences, are a common feature of the ccRCC and the cause of TRT.</p><p>The same group reported previously that mutations in <italic>SETD2</italic> are linked to reduced double-strand break repair and activation of the p53 pathway. In the current manuscript, they document a significant level of TRT in RCC, in which increased <italic>BCL2</italic> gene expression is associated with TRT into the body of the <italic>BCL2</italic> gene. In addition, chimeric transcripts also arise from TRT, and the fusion transcript <italic>CTSC-RAB38</italic> is found in 20% of RCC. Using <italic>SETD2</italic> knockout cells, the authors also documented an increase in TRT as compared with wild-type cells. Further, the authors report the formation of RNA chimeras resulting from the improper splicing of the chimeric RNAs resulting from the transcriptional read-through.</p><p>Overall, this manuscript is interesting, although their main focus, as suggested in the title, of RNA chimeras has been reported previously for ccRCC in the Nature paper published a few years ago (Nature 499,43-49 (04 July 2013) doi:10.1038/nature12222). Furthermore, a recent study in neuroblastoma revealed pervasive TRT in response to osmotic shock, which was seemingly dependent on IP3R activation (Vilborg et al. Mol Cell 2015).</p><p>Essential revisions:</p><p>While the technical aspect of this study is very well-done and the findings offer a different conceptual framework for the cancer transcriptome, they are only based on correlations and it remains unclear if they contribute to malignancy and are mechanistically linked to loss of <italic>SetD2</italic>. Without further functional evidence that the absence of <italic>SETD2</italic> directly accounts for enhanced read-through the current work remains too preliminary. This could be achieved by knockdown of <italic>SETD2</italic> in wild-type RCC cell lines followed by TRT measurement to determine whether loss of <italic>SETD2</italic> function would reduce TRT. Using inducible <italic>SETD2</italic> in <italic>SETD2</italic> mutant RCC cell lines, one could potentially perform short term TRT measurement upon induction of <italic>SETD2</italic> expression and/or provide colony suppression assays to document the inability to reconstitute <italic>SETD2</italic> expression in mutant cell lines.</p><p>Minor points:</p><p>1) The authors claim that <italic>SETD2</italic> mutations cause the improper readout using Caki-2 cell lines as a control. The Caki-2 cell line is also a ccRCC cell line, and the other lines used in this study show lower levels of <italic>Setd2</italic> transcription. However, the authors should show that mutations in <italic>BAP, PBRM1</italic> or <italic>VHL</italic> do not show any transcriptional read-through before arriving at that conclusion. It would be informative if the authors compared the levels of <italic>Setd2</italic> with a cell line like HEK293, to get an idea as to how high it is expressed in Caki-2 cells relative to a 'normal' cell line.</p><p>2) The authors do not discuss or offer any explanations as to why the RNA chimera skips the last exon of the preceding gene and the first exon of the following gene. A comment on that observation would be interesting in the Discussion.</p><p>3) The authors should discuss the following points. Further work will be necessary to document whether chimeric transcripts produce functional oncoproteins and whether TRT results in transcripts that could increase the production of downstream genes, such as <italic>BCL2</italic>. The latter could be studied in future work through ribosome profiling and footprinting. Furthermore, direct evidence that a chimeric transcript (since it is unclear if these are indeed translated) has oncogenic functions will have to be studied in the future to justify the proposed model.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.09214.026</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>Essential revisions:</italic></p><p><italic>While the technical aspect of this study is very well-done and the findings offer a different conceptual framework for the cancer transcriptome, they are only based on correlations and it remains unclear if they contribute to malignancy and are mechanistically linked to loss of</italic> SetD2<italic>. Without further functional evidence that the absence of</italic> SETD2 <italic>directly accounts for enhanced read-through the current work remains too preliminary. This could be achieved by knockdown of</italic> SETD2 <italic>in wild-type RCC cell lines followed by TRT measurement to determine whether loss of</italic> SETD2 <italic>function would reduce TRT.</italic></p><p>Following the reviewers’ request, we now provide direct measurements of transcription read-through upon <italic>SETD2</italic> depletion in wild-type (wt) ccRCC cells. These were achieved using two distinct approaches: (a) Analysis of RNA-seq data from <italic>SETD2</italic> wt and <italic>SETD2</italic>-knockout ccRCC cells (<xref ref-type="fig" rid="fig3">Figure 3E,F</xref>) and (b) RT-qPCR analysis of transcription read-through in three different genes (<italic>MRPL23, SEL1L3 and FAM46A)</italic> following RNAi-mediated knockdown of <italic>SETD2</italic> in a wt ccRCC cell line (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). These additional data further support our conclusion that <italic>SETD2</italic> is necessary to prevent transcription read-through.</p><p><italic>Using inducible</italic> SETD2 <italic>in</italic> SETD2 <italic>mutant RCC cell lines, one could potentially perform short term TRT measurement upon induction of</italic> SETD2 <italic>expression and/or provide colony suppression assays to document the inability to reconstitute</italic> SETD2 <italic>expression in mutant cell lines. Without these experiments, the manuscript would not be acceptable for publication.</italic></p><p>To evaluate if wt <italic>SETD2</italic> can rescue the transcription read-through phenotype, we performed single-molecule RNA FISH upon transient transfection of mutant ccRCC cell lines with wt <italic>SETD2</italic>. We used FISH probes designed against a segment of the RNA transcript encoded by the intergenic region downstream of the canonical termination site of two different genes (<italic>MRPL23</italic> and <italic>SEL1L3</italic>, <xref ref-type="fig" rid="fig4">Figure 4</xref>). These new data show that reconstitution of <italic>SETD2</italic> activity in mutant ccRCC cells rescues the transcription termination defects.</p><p><italic>Minor points:1) The authors claim that</italic> SETD2 <italic>mutations cause the improper readout using Caki-2 cell lines as a control. The Caki-2 cell line is also a ccRCC cell line, and the other lines used in this study show lower levels of</italic> Setd2 <italic>transcription. However, the authors should show that mutations in</italic> BAP, PBRM1 <italic>or</italic> VHL <italic>do not show any transcriptional read-through before arriving at that conclusion. It would be informative if the authors compared the levels of</italic> Setd2 <italic>with a cell line like HEK293, to get an idea as to how high it is expressed in Caki-2 cells relative to a 'normal' cell line.</italic></p><p>As we show in <xref ref-type="fig" rid="fig2">Figure 2C</xref>, ccRCC samples with mutations in <italic>BAP, PBRM1</italic> or <italic>VHL</italic> do have transcription read-through. However, we show that mutations in <italic>SETD2</italic> correlate significantly with higher levels of read-through. In the revised manuscript we now present new data showing that loss of <italic>SETD2</italic> is sufficient to cause widespread transcription read-through in a wt ccRCC cell line. Moreover, we show that ectopic expression of <italic>SETD2</italic> in a mutant ccRCC cell line rescues the termination defects. In addition, following the referees’ suggestion, we now include HEK293 cells in the comparative analysis shown in <xref ref-type="fig" rid="fig3">Figure 3A</xref>. These new data reveal that HEK293 and Caki-2 cells express <italic>SETD2</italic> at similar levels.</p><p><italic>2) The authors do not discuss or offer any explanations as to why the RNA chimera skips the last exon of the preceding gene and the first exon of the following gene. A comment on that observation would be interesting in the Discussion.</italic></p><p>We show in <xref ref-type="fig" rid="fig7">Figure 7B</xref> that the splicing pattern of the chimeras join the second-last exon of the upstream gene with the second exon of the downstream gene. We suggest that this pattern is in agreement with the exon definition model according to which the absence of transcription termination evicts the last 3’ss of the upstream gene favouring the use of the first 3’ss that emerges from the downstream gene. This model explains why the RNA chimeras skip the last exon of the upstream gene and the first exon of the downstream gene. We now comment this model in the Discussion.</p><p><italic>3) The authors should discuss the following points. Further work will be necessary to document whether chimeric transcripts produce functional oncoproteins and whether TRT results in transcripts that could increase the production of downstream genes, such as</italic> BCL2<italic>. The latter could be studied in future work through ribosome profiling and footprinting. Furthermore, direct evidence that a chimeric transcript (since it is unclear if these are indeed translated) has oncogenic functions will have to be studied in the future to justify the proposed model.</italic></p><p>These points are now discussed in the revised manuscript.</p></body></sub-article></article>